Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5JDYO)

Drug Name

4-(1H-IMIDAZOL-1-YL)PHENOL Drug Info

Synonyms

4-(Imidazol-1-yl)phenol; 10041-02-8; 4-(1h-imidazol-1-yl)phenol; 4-Imidazol-1-yl-phenol; 4-(1-Imidazolyl)Phenol; Phenol, 4-(1H-imidazol-1-yl)-; 1-(p-Hydroxyphenyl)imidazole; 1-(4-Hydroxyphenyl)imidazole; p-(1-imidazolyl)phenol; CYKCUAPYWQDIKR-UHFFFAOYSA-N; 4-imidazolylphenol; (1H& imidazol& 1& yl)phenol (Compound 1); EINECS 233-121-4; 4-imidazol-1-ylphenol; 4m5r; p-(Imidazol-1-yl)phenol; ACMC-209vy5; AC1Q78RW; AC1Q4YG7; 4-(1H-imidazol-yl)phenol; 4(1H-imidazol-1-yl)phenol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 82315
CAS Number: CAS 10041-02-8
TTD Drug ID: DM5JDYO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nitric-oxide synthase inducible (NOS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
SD-6010	DM9DEYL	Osteoarthritis	FA00-FA05	Phase 3	[3]
MPL-S	DMNDCFY	Endotoxic shock	1G41	Phase 3	[4]
Pimagedine HCl	DMPWH30	Diabetic kidney disease	GB61.Z	Phase 2/3	[5]
GW274150	DMZMCB1	Asthma	CA23	Phase 2	[6]
BXT-51072	DMD8GNB	Cardiovascular disease	BA00-BE2Z	Phase 2	[7]
HP-228	DMNZ35F	Postoperative pain	MG30-MG3Z	Phase 2	[8]
CR-3294	DMHJEZS	Diarrhea	ME05.1	Phase 2	[9]
KD-7040	DME1WV2	Pain	MG30-MG3Z	Phase 2	[10]
LT-1951	DM5N04G	Coronary artery disease	BA80	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nitric-oxide synthase inducible (NOS2)	TTF10I9	NOS2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3	A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
4	Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
5	Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
6	GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
7	Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
8	HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
9	Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
10	WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
11	Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.